Mustang Bio Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Mustang Bio (MBIO) Tops Q1 EPS by 2c
May 10, 2019 7:40 AM EDTMustang Bio (NASDAQ: MBIO) reported Q1 EPS of ($0.34), $0.02 better than the analyst estimate of ($0.36).
As of March 31, 2019, Mustangs consolidated cash, cash equivalents, short-term investments (certificates of deposit) and restricted cash totaled $41.1 million, compared to $34.6 million as of December 31, 2018, an increase of $6.5 million for the quarter.Research and development expenses were $7.0 million for the first quarter of 2019, compared to $4.3 million for the first quarter of 2018. Non-cash, stock-based compensation expenses included in research and development were $0.1 million for first quarter of 2019, compared to $1.5 million for the first quarter of 2018.Research and development... MoreFortress Biotech (FBIO) Tops Q1 EPS by 60c, Slight Beat on Revenues
May 10, 2019 7:39 AM EDTFortress Biotech (NASDAQ: FBIO) reported Q1 EPS of $0.02, $0.60 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $6.48 million versus the consensus estimate of $6.41 million.
As of March 31, 2019, Fortress consolidated cash, cash equivalents, short-term investments (certificates of deposit), and restricted cash totaled $137.5 million, compared to $99.2 million as of December 31, 2018, an increase of $38.3 million for the quarter.Fortress net revenue totaled $6.5 million for the first quarter of 2019, compared to $5.9 million for the first quarter of 2018.Research and development expenses were $23.3 million for the first quarter of 2019, of which $22.6 million... More